Abstract
Nephrogenic systemic fibrosis (NSF), unknown before March 1997 and first described in 2000, is a systemic disorder characterised by widespread tissue fibrosis. The first known case occurred in 1997, after the use of gadolinium-based contrast agents (GBCAs) at high doses in patients with renal failure had become routine. An overwhelming majority occurred within weeks to months after injection of a GBCA. This note comprises guidelines on the prevention of NSF.
Highlights
Gadolinium-DTPA (Gd-DTPA), introduced in 1988, is the first paramagnetic contrast agent approved for clinical use in MR imaging
Nephrogenic systemic fibrosis (NSF), unknown before March 1997 and first described in 2000, is a systemic disorder characterised by widespread tissue fibrosis
Known as nephrogenic fibrosing dermopathy (NFD) because of its dominant cutaneous findings, the nomenclature was revised in recent years to reflect an increased understanding of its systemic effects
Summary
Radiodiagnosis Division, University of Stellenbosch and Tygerberg Academic Hospital, Parow, Western Cape, South Africa. The first known case occurred in 1997, after the use of gadolinium-based contrast agents (GBCAs) at high doses in patients with renal failure had become routine. The link between nephrogenic systemic fibrosis (NSF) and GBCAs was recognised in 2006. Gadolinium-DTPA (Gd-DTPA), introduced in 1988, is the first paramagnetic contrast agent approved for clinical use in MR imaging. Nephrogenic systemic fibrosis (NSF), unknown before March 1997 and first described in 2000, is a systemic disorder characterised by widespread tissue fibrosis. Known as nephrogenic fibrosing dermopathy (NFD) because of its dominant cutaneous findings, the nomenclature was revised in recent years to reflect an increased understanding of its systemic effects. Typical is the unique histopathology of NSF that includes thickened collagen bundles with surrounding clefts, increased dermal mucin deposition, proliferation of dendritic cells and increased elastic fibers.[1]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
